Viral Hepatitis

You have full text access to this OnlineOpen article

Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients†

  1. Montserrat Laguno1,‡,*,
  2. Carmen Cifuentes2,
  3. Javier Murillas3,
  4. Sergio Veloso4,
  5. Maria Larrousse1,
  6. Antoni Payeras2,
  7. Lucia Bonet3,
  8. Francese Vidal4,
  9. Ana Milinkovic1,
  10. Antoni Bassa2,
  11. Concha Villalonga3,
  12. Iñaki Pérez5,
  13. Cristina Tural6,
  14. Maria Martínez-Rebollar1,
  15. Marta Calvo1,
  16. Jose Luis Blanco1,
  17. Estaban Martínez1,
  18. Jose M. Sánchez-Tapias7,
  19. Jose M. Gatell1,
  20. Jose Mallolas1

Article first published online: 9 SEP 2008

DOI: 10.1002/hep.22598

Issue

Hepatology

Hepatology

Volume 49, Issue 1, pages 22–31, January 2009

Additional Information

How to Cite

Laguno, M., Cifuentes, C., Murillas, J., Veloso, S., Larrousse, M., Payeras, A., Bonet, L., Vidal, F., Milinkovic, A., Bassa, A., Villalonga, C., Pérez, I., Tural, C., Martínez-Rebollar, M., Calvo, M., Blanco, J. L., Martínez, E., Sánchez-Tapias, J. M., Gatell, J. M. and Mallolas, J. (2009), Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology, 49: 22–31. doi: 10.1002/hep.22598

Author Information

  1. 1

    Infectious Diseases Service. Hospital Clínic, Barcelona, Spain

  2. 2

    Internal Medicine Service, Hospital Son Llàtzer, Palma de Mallorca, Spain

  3. 3

    Internal Medicine Service, Hospital Son Dureta, Palma de Mallorca, Spain

  4. 4

    Internal Medicine Service, Hospital Joan XXIII and Universitat Rovira i Virgili, Tarragona, Spain

  5. 5

    Biostatistics, Hospital Clínic, Barcelona

  6. 6

    Internal Medicine Service, Hospital Germans Trias i Pujol, Badalona, Spain

  7. 7

    Hepatology Service, Hospital Clínic, Barcelona, Spain

  1. ‡

    fax: (34) 3-4515424

*Infectious Diseases Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain

  1. †

    Potential conflict of interest: Dr. Payeras is on the speakers' bureau of Roche and Abbott Laboratories. Dr. Mallolas is a consultant for Roche and Schering-Plough.

Publication History

  1. Issue published online: 28 DEC 2008
  2. Article first published online: 9 SEP 2008
  3. Accepted manuscript online: 9 SEP 2008 12:00AM EST
  4. Manuscript Accepted: 21 AUG 2008
  5. Manuscript Received: 4 JUL 2008

Funded by

  • Spanish Ministry of Health. Grant Number: FIS 2007
  • “Institut d' Investigacions Biomèdiques August Pi i Sunyer” (IDIBAPS)
  • “Red Temática de Investigación en SIDA (Red de grupos del FIS)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (370K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ziba Jalali, Jürgen K. Rockstroh, Antiviral Drugs and the Treatment of Hepatitis C, Current HIV/AIDS Reports, 2012,

    CrossRef

  2. 2
    Masao Omata, Tatsuo Kanda, Ming-Lung Yu, Osamu Yokosuka, Seng-Gee Lim, Wasim Jafri, Ryosuke Tateishi, Saeed S. Hamid, Wan-Long Chuang, Anuchit Chutaputti, Lai Wei, Jose Sollano, Shiv Kumar Sarin, Jia-Horng Kao, Geoffrey W. McCaughan, APASL consensus statements and management algorithms for hepatitis C virus infection, Hepatology International, 2012, 6, 2, 409

    CrossRef

  3. 3
    M. Rumi, A. Aghemo, G. M. Prati, Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19,
    Direct Link:
  4. 4
    Kazuya Kamada, Ikuo Shoji, Lin Deng, Chie Aoki, Suratno Lulut Ratnoglik, Takaji Wakita, Hak Hotta, Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production, Microbes and Infection, 2012, 14, 1, 69

    CrossRef

  5. 5
    Mark S. Sulkowski, Hepatitis C virus-human immunodeficiency virus coinfection, Liver International, 2012, 32,
    Direct Link:
  6. 6
    Paulina Deming, Ian R. McNicholl, Coinfection with Human Immunodeficiency Virus and Hepatitis C Virus: Challenges and Therapeutic Advances, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 4
    Direct Link:
  7. 7
    Laura García-Jurado, Itziar Oyagüez, Miguel Ángel Casado, Cristina Tural, Juan González-García, Enrique Ortega, Juan Antonio Pineda, Evaluación económica de la elastografía de transición (FibroScan®) en el diagnóstico de fibrosis hepática en pacientes con hepatitis C coinfectados con VIH, Enfermedades Infecciosas y Microbiología Clínica, 2011,

    CrossRef

  8. 8
    Deepak Joshi, John O'Grady, Doug Dieterich, Brian Gazzard, Kosh Agarwal, Increasing burden of liver disease in patients with HIV infection, The Lancet, 2011, 377, 9772, 1198

    CrossRef

  9. 9
    Aarthi Chary, Mark Holodniy, Interferon combination therapy for HIV/hepatitis C virus coinfection, Immunotherapy, 2011, 3, 9, 1087

    CrossRef

  10. 10
    Deepak Joshi, John O'Grady, Chris Taylor, Nigel Heaton, Kosh Agarwal, Liver transplantation in human immunodeficiency virus-positive patients, Liver Transplantation, 2011, 17, 8
    Direct Link:
  11. 11
    Josep Mallolas Masferrer, María Martínez-Rebollar, Montserrat Laguno Centeno, Tratamiento de la hepatitis por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana, Gastroenterología y Hepatología, 2011, 34, 8, 558

    CrossRef

  12. 12
    Sihai Zhao, Enqi Liu, Ping Chen, Daxin Cheng, Shemin Lu, Qi Yu, Yanli Wang, Kena Wei, Penghui Yang, A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials, Clinical Therapeutics, 2010, 32, 9, 1565

    CrossRef

  13. 13
    Eva Van den Eynde, Juan Manuel Tiraboschi, Cristina Tural, Ricard Solà, José Antonio Mira, Daniel Podzamczer, Antoni Jou, Nuria Cañete, Juan Antonio Pineda, Albert Pahissa, Manuel Crespo, Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients, AIDS, 2010, 24, 7, 975

    CrossRef

  14. 14
    Patrice Cacoub, Philippe Halfon, Eric Rosenthal, François Bailly, Firouze Bani Sadr, Yves Benhamou, Stéphane Chevaliez, Jean Michel Pawlotsky, Lionel Piroth, Yazdan Yazdanpanah, Stanislas Pol, Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009, Journal of Hepatology, 2010, 53, 2, 230

    CrossRef

  15. 15
    Panel de expertos de Gesida, Plan Nacional sobre el Sida, Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010), Enfermedades Infecciosas y Microbiología Clínica, 2010, 28, 6, 362.e1

    CrossRef

  16. 16
    Yalena Amador-Cañizares, Santiago Dueñas-Carrera, Early Interferon-Based Treatment After Detection of Persistent Hepatitis C Virus Infection: A Critical Decision, Journal of Interferon & Cytokine Research, 2010, 30, 11, 817

    CrossRef

  17. 17
    L. Milazzo, I. Caramma, C. Mazzali, M. Cesari, M. Olivetti, M. Galli, S. Antinori, Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study, Journal of Antimicrobial Chemotherapy, 2010, 65, 4, 735

    CrossRef

  18. 18
    K. Seden, D. Back, S. Khoo, New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals, Journal of Antimicrobial Chemotherapy, 2010, 65, 6, 1079

    CrossRef

  19. 19
    Tahany Awad, Kristian Thorlund, Goran Hauser, Davor Stimac, Mahasen Mabrouk, Christian Gluud, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials, Hepatology, 2010, 51, 4
    Direct Link:
  20. 20
    Graham R. Foster, Pegylated Interferons for the Treatment of Chronic Hepatitis C, Drugs, 2010, 70, 2, 147

    CrossRef

  21. 21
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  22. 22
    Martin Potter, Marina B Klein, Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B, HIV Therapy, 2009, 3, 2, 189

    CrossRef

  23. 23
    Hui-Hui Tan, Paul Martin, Current treatment of chronic HBV infection: A North American perspective, Current Hepatitis Reports, 2009, 8, 4, 148

    CrossRef

  24. 24
    J. Berenguer, J. Gonzalez-Garcia, J. Lopez-Aldeguer, M. A. Von-Wichmann, C. Quereda, A. Hernando, J. Sanz, C. Tural, E. Ortega, J. Mallolas, I. Santos, P. Miralles, M. L. Montes, J. M. Bellon, H. Esteban, Pegylated interferon  2a plus ribavirin versus pegylated interferon  2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients, Journal of Antimicrobial Chemotherapy, 2009, 63, 6, 1256

    CrossRef

  25. 25
    Alfonso Iorio, Emanuela Marchesini, Tahany Awad, Lise Lotte Gluud, Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus, The Cochrane Library,
    Direct Link:
  26. 26
    Rebekah G. Gross, Ira M. Jacobson, Genotype 1: Standard Treatment,
    Direct Link:
View Full Article (HTML) Get PDF (370K)